Medico Intercontinental Ltd is engaged in the business of trading pharmaceutical products. It provides a platform for all research-based biopharmaceutical companies. Its product categories include Gastro, Uro, Nutrition, Cosmetology, Health devices, Hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE-D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT-4, ZIFT SL-250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY, RELIBEN SUSP, ZIFT SUSP-200, MGCIPACT EYE DROP, OROFACT-PASTE (lamy), OROFACT MOUTH ULCER GEL, CAMBOGIA, LUBRIACT, HIZEN, and CALAMED LOTION. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.As of 25 May 2026, Medico Intercontinental Limite share price is ₹21.97. The stock opened at ₹21.59, compared to its previous close of ₹21.59. During today's trading session, Medico Intercontinental Limite share price moved in the range of ₹21.00 to ₹21.98, with an average price of ₹21.49 for the day. Looking at its last 52-week, the stock has touched a low of ₹21.00 and a high of ₹21.98.
The market capitalization of Medico Intercontinental Limite is ₹22 Crs, with a P/E ratio of -2.0 and a dividend yield of 0.00%.